What is Biolistic Particle Delivery System Market?
A biolistic particle delivery system is used to transmit genetic information to cells by administering specific RNA or DNA. RNA or DNA is coated over a transporter, which may be an elemental particle of heavy metal, and released with high-velocity acceleration to perforate the cell membrane in a biolistic particle delivery device. This genetic knowledge from plasmid DNA is then used to turn target tissue to achieve the desired effects. As a result, the biolistic particle delivery mechanism plays a critical role in altering the cell's genetic structure by adding foreign material. The biolistic particle delivery system is not only used in humans, but also in plants and animals where drought tolerance genes are added.
The market study is being classified, by Application (Genetic vaccination, Cancer gene therapy, Immunomodulation, Genetic pharmacology and Others) and major geographies with country level break-up.
Bio-Rad Laboratories, Inc. (United States), Chintek Technology Co., Ltd. (Taiwan), Thermo Fisher Scientific, Inc. (United States), Wealtech Corporation (United States), Life Technologies Corporation (United States), Harvard Bioscience, Inc. (United States), DuPont de Nemours, Inc. (United States), Ningbo Scientz Biotechnology Co., Ltd. (China) and Biotechnologies, Inc. (India) are some of the key players profiled in the study.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Biolistic Particle Delivery System market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Biolistic Particle Delivery System market by Type, Application and Region.
On the basis of geography, the market of Biolistic Particle Delivery System has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Rise in the Prevalence of Genetic Disorders
- Increasing Awareness and Treatment-seeking Rate for Gene Therapy
- Advancements in the Field of Genetic Engineering
- Ethical Issues related to Gene Alteration
- Increase in Research and Development Activities for Genomic Medicine
- Rising Investment by Key Players
In July 2020 Novartis International AG and Sangamo Therapeutics announce collaboration for research and development activities in the field of genomic medicine.
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Biolistic Particle Delivery System Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry
Frequently Asked Questions (FAQ):
1. Which factors would majorly drive the Biolistic Particle Delivery System Market?
"Rise in the Prevalence of Genetic Disorders
" is seen as one of major growth factors of Biolistic Particle Delivery System Market in years to come.
2. Can we have customized study for Biolistic Particle Delivery System Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.